{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006441","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.235368+00:00","generated_at":"2026-06-09T09:25:17.753195+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioCryst enrolls first patient in proof-of-concept trial for oral Factor D inhibitor BCX10013","bullets":["First patient enrolled in open-label, multicenter dose-escalation trial of BCX10013 in up to 15 PNH patients.","Primary endpoints: treatment-emergent AEs, graded lab abnormalities; secondary: LDH, hemoglobin, transfusion-free rate.","If best-in-class profile confirmed in PNH, company plans to advance to pivotal program in renal complement diseases like IgAN.","Trial conducted in countries without standard-of-care complement inhibitor therapy; NCT06100900."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006441","json":"https://secwatch.observer/filing/0001171843-23-006441.json","markdown":"https://secwatch.observer/filing/0001171843-23-006441.md","text":"https://secwatch.observer/filing/0001171843-23-006441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/0001171843-23-006441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/f8k_102623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:25:17.753195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}